TP53 and B-cell chronic lymphocytic leukemia: Due to its strong prognostic and predictive value, TP53 mutation testing is now recommended before initiating treatment in CLL patients, and repeated testing is advised before each line of therapy, as clonal evolution may lead to the emergence of new TP53 mutations over time [181,182,183].